NeuroKaire report finds depressed Americans self-treat with cannabis, screens and weight-loss drugs

A new NeuroKaire report based on 18,341 U.S. adults says 3,737 people with self-reported depression are increasingly using DIY treatment stacks instead of waiting for standard care. The findings point to a growing gap between how Americans with depression manage symptoms and how the mental health system delivers treatment. Why it matters: - NeuroKaire’s report suggests many Americans with depression are already self-managing symptoms with cannabis, screens, telehealth, weight-loss drugs and other behaviors instead of relying on the traditional prescription trial-and-error model. - The findings point to real costs in income, insurance coverage and access to care for people with depression. - The report also raises new questions about how wellness trends, social media and emerging drugs like GLP-1 medications intersect with mental health treatment. What happened: - NeuroKaire released The Self-Medication Generation, the first installment in its Depression in America Research Series. - The report is based on a national survey of 18,341 U.S. adults fielded by Prosper Insights & Analytics between January and February 2026. - Of the respondents, 3,737 self-reported a depression diagnosis. - NeuroKaire analyzed the data and found that depressed adults across generations are building their own treatment stacks using fragmented advice from sources such as Reddit, TikTok and peers. The details: - Adults with depression earn 12% to 23% less than their peers, and the pay gap widens with age. - By the Boomer generation, depressed adults earn nearly a quarter less than peers. - Nearly half of depressed adults, 47%, are on government health insurance. - Among depressed Millennials, 40% are on government insurance, which is 80% more than their Millennial peers. - More than one in four depressed Gen Z adults, 27%, is unemployed. - Nearly one in three adults with depression, 28%, does not have a credit card. - The report says the lack of credit can make it harder to float copays, buy supplements or absorb the cost of a medication that does not work. - Half of Gen Z adults with depression, 50%, use marijuana, compared with 44% of their peers. - Boomers with depression use marijuana 71% more than their peers. - Seven in ten Gen Z CBD users with depression, 70%, say they use CBD specifically for mental wellness. - Boomers with depression are 69% more likely than their peers to use CBD for the same reason. - Adults with depression are 67% more likely than the general population to take prescription weight-loss drugs. - Boomers with depression show the largest gap, at 117% more than their peers. - Adults with depression are 50% to 75% more likely to use over-the-counter weight-loss supplements. - Depressed Gen Z adults are more likely than non-depressed peers to watch their calorie intake, at 46%, and exercise at least three times a week, at 29%. - Two-thirds of Gen Z adults with depression, 67%, play video games as a primary leisure activity. - Thirty-five percent spend free time in online communities, 66% more than their peers. - Boomers with depression are 100% more likely than their peers to use telehealth. - Boomers with depression are also 52% more likely to participate in online communities. - Thirty-three percent of depressed Gen Z adults say crafting is a hobby, 83% more than their peers. - Forty-five percent say they read books. - Boomers with depression are 67% more likely than their peers to say social media influences medicine purchases. - Boomers with depression are 75% more likely to be influenced by mobile video and 54% more likely to be influenced by product reviews. - About one in four adults with depression regularly searches online for medical information. - Boomers with depression search for medical information online 67% more than their peers. - NeuroKaire says the full report is available at NeuroKaire’s website . Between the lines: - The report argues that the mental health system’s standard approach can take 12 to 18 months on average to find the right antidepressant. - Each failed attempt can mean more side effects, more appointments, more time out of work and more money spent on treatment. - NeuroKaire CEO Dr. Talia Cohen Solal said one-size-fits-all treatment does not work and that the healthcare system has not yet caught up with what patients already know. - The data also challenges the assumption that younger adults are the main driver of media-influenced medicine buying. - Boomers with depression appear to be the most digitally engaged generation in the report when it comes to health decisions. What’s next: - NeuroKaire plans to continue its Depression in America Research Series. - The company says its precision psychiatry platform aims to match treatment to individual neurobiology sooner than the current trial-and-error model. - The report highlights GLP-1 medications and their interaction with depression and antidepressants as an emerging clinical issue. The bottom line: - The report portrays depression treatment in the U.S. as increasingly self-directed, digitally shaped and mismatched with the pace of traditional care.